BridgeBio Pharma (BBIO) Non-Current Deffered Revenue (2023 - 2026)

BridgeBio Pharma has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting $11.8 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $11.8 million, down 32.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.8 million (down 32.74% YoY), and the FY2025 annual result was $13.1 million, down 23.49% from the prior year.
• Non-Current Deffered Revenue came in at $11.8 million for Q1 2026 at BridgeBio Pharma, down from $13.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $19.9 million in Q1 2024 to a low of $3.7 million in Q4 2023.
• The 4-year median for Non-Current Deffered Revenue is $15.8 million (2024), against an average of $14.6 million.
• Across the five-year window, Non-Current Deffered Revenue jumped 358.68% in 2024 and plunged 32.74% in 2026, its largest moves.
• BridgeBio Pharma's Non-Current Deffered Revenue stood at $3.7 million in 2023, then surged by 358.68% to $17.1 million in 2024, then retreated by 23.49% to $13.1 million in 2025, then dropped by 9.97% to $11.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $11.8 million (Q1 2026), $13.1 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.